EGFR and non-small cell lung carcinoma: expanding the landscape of potential EGFR inhibitors for EGFR-driven cancers, including non-small cell lung cancer (NSCLC), based on the validation and confirmation scores obtained from molecular docking simulations and molecular (MD) analysis.